Sanofi Gets EU Approval
Sanofi's Cenrifki is approved in the EU as the first disability-targeting treatment for non-relapsing secondary progressive multiple sclerosis
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.